In conclusion, accumulating evidence in mice and humans shows that VEGFR3 dysregulation along with increased VEGF-C ligand is observed in secondary lymphedema, possibly due to accompanying chronic inflammatory conditions. This evidence concerns the gene FLT4 and lymphedema.